130 related articles for article (PubMed ID: 37572680)
1. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
Serra-Burriel M; Juanola A; Serra-Burriel F; Thiele M; Graupera I; Pose E; Pera G; Grgurevic I; Caballeria L; Piano S; van Kleef L; Reichert M; Roulot D; Pericàs JM; Schattenberg JM; Tsochatztis EA; Guha IN; Garcia-Retortillo M; Hernández R; Hoyo J; Fuentes M; Expósito C; Martínez A; Such P; Madir A; Detlefsen S; Tonon M; Martini A; Ma AT; Pich J; Bonfill E; Juan M; Soria A; Carol M; Gratacós-Ginès J; Morillas RM; Toran P; Navarrete JM; Torrejón A; Fournier C; Llorca A; Arslanow A; de Koning HJ; Cucchietti F; Manns M; Newsome PN; Hernáez R; Allen A; Angeli P; de Knegt RJ; Karlsen TH; Galle P; Wong VW; Fabrellas N; Castera L; Krag A; Lammert F; Kamath PS; Ginès P;
Lancet; 2023 Sep; 402(10406):988-996. PubMed ID: 37572680
[TBL] [Abstract][Full Text] [Related]
2. LiverRisk score: An accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population.
Liu S; Chen X; Jiang X; Yin X; Fekadu G; Liu C; He Y; Chen H; Ni W; Wang R; Zeng QL; Chen Y; Yang L; Shi R; Ju SH; Shen J; Gao J; Zhao L; Ming WK; Zhong VW; Teng GJ; Qi X
Med; 2024 Jun; 5(6):570-582.e4. PubMed ID: 38554711
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.
van Kleef LA; Francque SM; Prieto-Ortiz JE; Sonneveld MJ; Sanchez-Luque CB; Prieto-Ortiz RG; Kwanten WJ; Vonghia L; Verrijken A; De Block C; Gadi Z; Janssen HLA; de Knegt RJ; Brouwer WP
Gastroenterology; 2024 Mar; ():. PubMed ID: 38513745
[TBL] [Abstract][Full Text] [Related]
4. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
5. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
[TBL] [Abstract][Full Text] [Related]
7. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis.
Thiele M; Detlefsen S; Sevelsted Møller L; Madsen BS; Fuglsang Hansen J; Fialla AD; Trebicka J; Krag A
Gastroenterology; 2016 Jan; 150(1):123-33. PubMed ID: 26435270
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study.
Sarvestany SS; Kwong JC; Azhie A; Dong V; Cerocchi O; Ali AF; Karnam RS; Kuriry H; Shengir M; Candido E; Duchen R; Sebastiani G; Patel K; Goldenberg A; Bhat M
Lancet Digit Health; 2022 Mar; 4(3):e188-e199. PubMed ID: 35216753
[TBL] [Abstract][Full Text] [Related]
11. Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.
Allotey J; Snell KI; Smuk M; Hooper R; Chan CL; Ahmed A; Chappell LC; von Dadelszen P; Dodds J; Green M; Kenny L; Khalil A; Khan KS; Mol BW; Myers J; Poston L; Thilaganathan B; Staff AC; Smith GC; Ganzevoort W; Laivuori H; Odibo AO; Ramírez JA; Kingdom J; Daskalakis G; Farrar D; Baschat AA; Seed PT; Prefumo F; da Silva Costa F; Groen H; Audibert F; Masse J; Skråstad RB; Salvesen KÅ; Haavaldsen C; Nagata C; Rumbold AR; Heinonen S; Askie LM; Smits LJ; Vinter CA; Magnus PM; Eero K; Villa PM; Jenum AK; Andersen LB; Norman JE; Ohkuchi A; Eskild A; Bhattacharya S; McAuliffe FM; Galindo A; Herraiz I; Carbillon L; Klipstein-Grobusch K; Yeo S; Teede HJ; Browne JL; Moons KG; Riley RD; Thangaratinam S
Health Technol Assess; 2020 Dec; 24(72):1-252. PubMed ID: 33336645
[TBL] [Abstract][Full Text] [Related]
12. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
[TBL] [Abstract][Full Text] [Related]
13. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
[TBL] [Abstract][Full Text] [Related]
14. Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis.
Labenz C; Toenges G; Zheng MH; Ding D; Myers RP; Galle PR; Armandi A; Ampuero J; Gómez MR; Bugianesi E; Anstee QM; Schattenberg JM
Eur J Intern Med; 2022 Apr; 98():53-60. PubMed ID: 35058147
[TBL] [Abstract][Full Text] [Related]
15. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.
Liu XD; Wu JL; Liang J; Zhang T; Sheng QS
World J Gastroenterol; 2012 Jun; 18(22):2784-92. PubMed ID: 22719186
[TBL] [Abstract][Full Text] [Related]
16. Development and multicenter validation of FIB-6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C.
Shiha G; Soliman R; Mikhail NNH; Alswat K; Abdo A; Sanai F; Derbala MF; Örmeci N; Dalekos GN; Al-Busafi S; Hamoudi W; Sharara AI; Zaky S; El-Raey F; Mabrouk M; Marzouk S; Toyoda H
Hepatol Res; 2022 Feb; 52(2):165-175. PubMed ID: 34767312
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation.
Guha IN; Harris R; Berhane S; Dillon A; Coffey L; James MW; Cucchetti A; Harman DJ; Aithal GP; Elshaarawy O; Waked I; Stewart S; Johnson PJ
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2330-2338.e1. PubMed ID: 30716478
[TBL] [Abstract][Full Text] [Related]
18. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
[TBL] [Abstract][Full Text] [Related]
19. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
[TBL] [Abstract][Full Text] [Related]
20. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
